Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.